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Background: The purpose of the study was to evaluate the applicability of 18F-labelled amyloid imaging positron
emission tomography (PET) agent [18F]flutemetamol to detect changes in brain beta-amyloid (Aβ) deposition
in vivo in APP23, Tg2576 and APPswe-PS1dE9 mouse models of Alzheimer's disease. We expected that the high
specific activity of [18F]flutemetamol would make it an attractive small animal Aβ imaging agent.
Methods: [18F]flutemetamol uptake in the mouse brain was evaluated in vivo at 9 to 22 months of age with an
Inveon Multimodality PET/CT camera (Siemens Medical Solutions USA, Knoxville, TN, USA). Retention in the frontal
cortex (FC) was evaluated by Logan distribution volume ratios (DVR) and FC/cerebellum (CB) ratios during the late
washout phase (50 to 60 min). [18F]flutemetamol binding to Aβ was also evaluated in brain slices by in vitro and
ex vivo autoradiography. The amount of Aβ in the brain slices was determined with Thioflavin S and anti-Aβ1−40
immunohistochemistry.
Results: In APP23 mice, [18F]flutemetamol retention in the FC increased from 9 to 18 months. In younger mice,
DVR and FC/CB50-60 were 0.88 (0.81) and 0.88 (0.89) at 9 months (N = 2), and 0.98 (0.93) at 12 months (N = 1),
respectively. In older mice, DVR and FC/CB50-60 were 1.16 (1.15) at 15 months (N = 1), 1.13 (1.16) and 1.35 (1.35) at
18 months (N = 2), and 1.05 (1.31) at 21 months (N = 1). In Tg2576 mice, DVR and FC/CB50-60 showed modest
increasing trends but also high variability. In APPswe-PS1dE9 mice, DVR and FC/CB50-60 did not increase with
age. Thioflavin S and anti-Aβ1−40 positive Aβ deposits were present in all transgenic mice at 19 to 22 months, and they
co-localized with [18F]flutemetamol binding in the brain slices examined with in vitro and ex vivo autoradiography.
Conclusions: Increased [18F]flutemetamol retention in the brain was detected in old APP23 mice in vivo. However, the
high specific activity of [18F]flutemetamol did not provide a notable advantage in Tg2576 and APPswe-PS1dE9 mice
compared to the previously evaluated structural analogue [11C]PIB. For its practical benefits, [18F]flutemetamol imaging
with a suitable mouse model like APP23 is an attractive alternative.
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Alzheimer's disease (AD) is the most common cause of
dementia. The main pathological findings in a typical
AD brain are neurofibrillary tangles and extracellular
neuritic plaques, mainly composed of a fibrillar form of
beta-amyloid (Aβ) peptide [1]. Methods based on mo-
lecular imaging have recently made it possible to assess
brain Aβ deposition in patients with AD. Positron emis-
sion tomography (PET) with the Aβ imaging agent [11C]
Pittsburgh compound B ([11C]PIB) first established this
as a valuable biomarker approach for evaluating changes
in Aβ deposition [2,3]. Several small animal PET im-
aging studies have also been performed with [11C]PIB,
but the results have not been consistent, probably
reflecting differences in specific activity of the tracer and
in the employed animal models [4-8]. Due to the short
half-life (T½ = 20.4 min) of
11C, 18F-labelled ligands for
Aβ imaging have been developed to extend the use of
amyloid PET to the centres without on-site radionuclide
production and tracer synthesis capacity. Due to their
practical benefits, the use of 18F-labelled tracers has also
raised interest in small animal imaging [9-11].
[18F]flutemetamol (2-(3-[18F]fluoro-4-(methylamino)phenyl)-
1,3-benzothiazol-6-ol, [18F]3′F-PiB, [18F]GE067) is a
18F-labelled analogue of [11C]PIB developed and marketed
by GE Healthcare (Buckinghamshire, UK). [18F]flutemetamol
PET has been shown to successfully differentiate between
patients with AD and healthy control subjects and to
perform similarly to [11C]PIB in this respect [12,13]. [18F]
flutemetamol has shown high test-retest reliability and
high specificity (96%, [12]) and sensitivity (93%, [12]) in
the detection of AD, and regional imaging results obtained
with it were consistent with AD plaque pathology in cor-
tical biopsy samples [14-16]. Based on these findings, [18F]
flutemetamol received FDA approval as a diagnostic agent
for the assessments of Aβ deposition in the brains of
adults evaluated for AD (FDA application number (NDA)
203137, GE Healthcare).
The present demonstration of principle study evaluated
the applicability of [18F]flutemetamol to detect and quan-
titate the changes in brain Aβ deposition in APP23,
Tg2576 and APPswe-PS1dE9 transgenic (TG) mouse
models of AD. We expected that the very high specific ac-
tivity of [18F]flutemetamol (>1 TBq/μmol) and thus lower
injected mass to transgenic animals would be beneficial in
small animal Aβ imaging. We also expected physical char-
acteristics and practical benefits of the 18F-radionuclide to
make [18F]flutemetamol an attractive preclinical Aβ im-
aging agent for preclinical studies.
Methods
Synthesis of [18F]flutemetamol
[18F]flutemetamol was produced with a FASTLab® Synthesizer
(GE Healthcare), following analogous procedures to thosedescribed in the patent, WO 2007/020400 A1 ‘Fluorin-
ation process of anilide derivatives and benzothiazole
fluorinate derivatives as in vivo imaging agents’. The spe-
cific radioactivity of [18F]flutemetamol was >1 TBq/μmol
at synthesis completion (N = 34). Radiochemical purity
exceeded 92%.
Animal models
All animal experiments were approved by the Animal
Experiment Board of the Province of Southern Finland
(permissions ESAVI-2010-04454/Ym-23 and ESAVI/
3899/04.10.07/2013) and the animal care complied with
the guidelines of the International Council of Laboratory
Animal Science (ICLAS). For in vivo imaging, we used
mice from three different TG mouse lines and their
strain-matched wild-type (WT) control animals. APP23
mice (APPswe [17]; Novartis Pharma (Basel, Switzerland);
N = 4 TG females, 2 TG males and 4 WT females) overex-
press the human 751 isoform of amyloid precursor protein
(APP), which contains the Swedish K670N/M671L double
mutation (APPswe). These mice develop Aβ plaques
with dense cores, similar to human plaques, vascular Aβ,
and neuron loss in the hippocampal CA1 pyramidal cell
layer [18]. Tg2576 mice (APPswe, B6; SJL-Tg(APPSWE)
2576Kha [19]; Taconic Europe. Ejby, Denmark; N = 4 TG
females, 3 WT females) express the human 695 isoform of
APPswe, which leads to expression of mutant Aβ, Aβ
plaques and memory deficits. APPswe-PS1dE9 mice
(B6C3-Tg(APPswe, PSEN1DE9)85Dbo/J [20]; Jackson La-
boratories, Bar Harbor, ME, USA; N = 4 TG females, 3 TG
males, 3 WT females) express a chimeric mouse/human
695 isoform of APPswe and mutant human Presenilin-1
(PS1dE9). The APPswe-PS1dE9 model mimics early-onset
familial AD, with elevated Aβ1-40 and Aβ1-42 levels, abun-
dant plaque pathology and memory deficits [21]. The
APPswe-PS1dE9 male mice used in ex vivo studies were a
kind gift from Professor H. Tanila from the University of
Eastern Finland. The animals were group-housed at the
Central Animal Laboratory of the University of Turku at
controlled temperature (21 ± 3°C) and humidity (55 ±
15%) and with a light period from 6:00 a.m. to 6:00 p.m.
TG and WT mice were fed with a soy-free diet (RM3 (E)
soya, 801710, Special Diets Service, Essex, UK). The ani-
mals had free access to food and tap water (summary of
animals, Table 1).
PET imaging
In vivo [18F]flutemetamol PET imaging was performed
at 9, 12, 15, 18 to 19, and 21 to 22 months of age (in all
48 PET scans). At each time point, 1 to 4 TG and WT
mice of each model were imaged (Table 1). Animals
were anaesthetized with isoflurane, and computed tom-
ography (CT) scans were acquired for attenuation cor-
rection and anatomical reference. Next, simultaneous
Table 1 Summary of the animals used for PET
experiments
APP23 Tg2576 APPswe-PS1dE9
TG WT TG WT TG WT
All mice (N) 6 4 4 3 7 3
In vivo PET (N)
9 mo 2 - 2 - 2 -
12 mo 1 - 4 2 3 2
15 mo 1 - 4 3 2 3
18 to 19 mo 2 - 2 2 2 3
21 to 22 mo 1 1 2 1 - -
27 mo - 1 - - - -
Ex vivo ARG (N)
18 to 19 mo - - - - 4 1
21 to 22 mo - - 1 1 - -
24 to 27 mo 2 2 - - - -
Amount of transgenic (TG) and wild-type (WT) animals used in this study. -,
not available; ARG, autoradiography; mo, age in months.

















18, 21 27 22 22 19 19
Aβ1-40 21, 27 24, 27 22 22 17, 19 19
Thioflavin
S
21, 27 24, 27 22 22 17, 19 19
Ages of the transgenic (TG) and wild-type (WT) mice from which the brain
cryosections for stainings in this study were obtained. ARG, autoradiography;
mo, age in months.
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of [18F]flutemetamol, a 60-min dynamic emission scan
was started with an Inveon PET/CT device (Siemens
Medical Solutions USA, Knoxville, TN, USA). Dynamic
imaging data were divided into 51 imaging frames (30 ×
10 s, 15 × 60 s, 4 × 300 s, 2 × 600 s); 3D imaging data were
rebinned into 2D sinograms with a Fourier rebinning al-
gorithm and then reconstructed with 2D filtered back-
projection, with a final voxel size of 0.78 × 0.78 × 0.80 mm.
Data were decay-corrected to the time of injection.
Analysis of PET data
PET data were analysed with Inveon Research Workplace
analysis software (Siemens Medical Solutions). PET and
CT images were co-registered, and volumes of interest
(VOI) were drawn under guidance of the CT image and a
mouse brain atlas to cover the whole brain, the frontal
cortex (FC) and the cerebellum (CB). Logan distribution
volume ratios (DVR) were calculated from the dynamic
PET data with the graphical method described by Logan
et al. [22], with CB as the reference tissue and fit time
from 5 to 60 min. FC/CB ratio curves were calculated
for the entire 60-min scan. In addition, static FC/CB re-
tention ratios were calculated only for the late phase
(50 to 60 min) of the scan.
In vitro binding experiment
In vitro binding experiments were performed as previ-
ously described [9] with 20-μm brain cryosections from
transgenic APP23 (N = 2), Tg2576 (N = 2) and APPswe-
PS1dE9 (N = 2) mice and wild-type control mice (N = 5)
that were sacrificed after in vivo studies were finalized
(Table 2). Briefly, the brain sections were incubated in0.5 MBq/ml [18F]flutemetamol in 2% human serum albu-
min for 30 min. The specificity of [18F]flutemetamol bind-
ing was evaluated by adding 10 μM non-radioactive PIB
(ABX, Radeberg, Germany) to the incubation solution, as
previously described [9]. [18F]flutemetamol binding was
detected using digital autoradiography (25 μm resolution).
Ex vivo autoradiography
Mice were anaesthetized with isoflurane and intraven-
ously injected with 9.1 ± 1.7 MBq (<7.5 ng, N = 11) of
[18F]flutemetamol. After the tracer had distributed for
30 min, the mice were sacrificed by cardiac puncture.
The brain was immediately dissected, rapidly frozen in
chilled isopentane, and cut to 20-μm cryosections at the
levels of the FC and CB. Sections were subsequently ex-
posed to an imaging plate for approximately 4 h. Plates
were read with a Fuji BAS-5000 analyser (resolution
25 μm). Regions of interest (ROI) were drawn onto the
FC and CB with the Aida Image Analyzer analysis pro-
gram (Aida 4.22, Raytest Isotopenmessgeräte GmbH,
Straubenhardt, Germany). ROIs were drawn onto at
least ten sections per animal, and mean intensity ratios
were calculated between the FC and the CB. In addition,
intensity profiles were drawn across the cortex that con-
tained Aβ deposits, and Aβ plaque-to-background ratios
were calculated for TG mice.
Ex vivo biodistribution
We further investigated [18F]flutemetamol binding to
different brain regions and structures inside the head in
WT male C57Bl/6N mice (N = 4) using ex vivo tissue
counting to better understand the observed binding
in vivo. Mice anaesthetized with isoflurane were injected
with 5.1 ± 0.9 MBq of [18F]flutemetamol, and the tracer
was allowed to distribute for 60 min. Mice were sacri-
ficed by cardiac puncture, and the brain was rapidly re-
moved. We dissected the forebrain, midbrain, hindbrain,
olfactory bulb, medulla, eyes, Harderian glands and
salivary glands, and we collected samples of FC, CB,
medulla and cranial bone. 18F-radioactivity was measured
with a gamma counter (2480 WIZARD2, PerkinElmer,
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background was subtracted and results were expressed
as the percentage of injected dose per gram of tissue
(% ID/g).Histological and immunohistochemical characterization of
brain Aβ deposits
In the same cryosections subjected to ex vivo and
in vitro autoradiography, fibrillar Aβ deposits were mea-
sured with the histochemical dye, Thioflavin S (ThS;
Sigma-Aldrich, St. Louis, MO, USA), as previously re-
ported [9]. Aβ pathology was also evaluated in adjacent
tissue sections by immunohistochemical staining with an
anti-Aβ1-40 (1:400; Millipore Corp., Billerica, MA, USA)
antibody, as previously reported [4]. The mice used for
brain histology are presented in Table 2. All sections
were post-fixed in 4% paraformaldehyde for 30 min be-
fore staining. Fluorescent images were examined with a
SteREO Lumar V.12 microscope (Carl Zeiss Microscopy
GmbH, Jena, Germany), and the images were captured
with a Zeiss Axiocam HRm S/N 1475 camera. Images of
3, 3′-diaminobenzidine stained sections were digitized
with the Pannoramic 250 Flash II digital slide scanner
(3DHistech, Budapest, Hungary), and the images were
captured with the Pannoramic Viewer software.Data analysis and statistics
All mean values are expressed as mean ± SD. Results for
less than three animals are given as individual values.
Linear regression analysis was performed using Graph-
Pad Prism software (version 5.01, La Jolla, CA, USA).
P values < 0.05 were considered statistically significant.Figure 1 In vivo [18F]flutemetamol retention in the brain of mouse m
[18F]flutemetamol injection are shown for (a) APP23, (b) Tg2576 and (c) AP
detected in the cerebral cortex of aged APP23 mice (18 and 21 months), b
(19 months) mice were similar to those of the young (9 months) transgeni
of animal in months.Results
PET imaging
Increased [18F]flutemetamol retention compared to young
TG animals and WT control animals was observed in the
FC of aged APP23 mice in visual assessment of the PET
images (Figure 1a), but not in aged Tg2576 or APPswe-
PS1dE9 mice (Figure 1b,c). Time-radioactivity curves in
Figure 2 illustrate the time-course of [18F]flutemetamol
uptake and washout in the FC and CB of representative
TG animals at the final PET evaluation (at 19 to 22 months
of age). The FC/CB ratios clearly increased over time
in old APP23 mice. On the contrary, in Tg2576 and
APPswe-PS1dE9 mice, the ratio was less than 1 in the
later time frames.
Logan DVRs calculated for the FCs of all TG and WT
animals are presented in Figure 3a. Each individual
mouse has its own symbol. The DVRs were increased in
the aged APP23 TG mice compared to young TG and
WT control animals. In younger TG mice, DVRs were
0.88 and 0.88 (9 months, N = 2) and 0.98 (12 months,
N = 1). In older TG mice, DVRs were 1.16 (15 months,
N = 1), 1.13 and 1.35 (18 months, N = 2), and 1.05
(21 months, N = 1). DVRs for WT animals were 0.83
(21 months, N = 1) and 0.98 (27 months, N = 1). The
DVRs of the Tg2576 mice showed an increasing trend,
reaching 1.24 and 1.11 (N = 2) at 22 months (WT 0.92,
N = 1). In contrast, the APPswe-PS1dE9 mice tended to
have lower DVRs (0.82 and 0.89, N = 2) than WT mice
(1.08 ± 0.12, N = 3) at 19 months.
FC/CB50-60 ratios calculated for the FCs of all TG and
WT animals are presented in Figure 3b. Each individual
mouse has its own symbol. The FC/CB50-60 ratios in-
creased with age in APP23 mice. The FC/CB50-60 valuesodels of AD. Sagittal PET/CT images summed over 40 to 60 min after
Pswe-PS1dE9 mice. Increased [18F]flutemetamol retention (yellow) was
ut signals in aged Tg2576 (19 and 22 months) and APPswe-PS1dE9
c mice. White arrows, frontal cortex; red arrows, cerebellum; mo, age
Figure 2 18F-radioactivity uptake and washout in the brain of
mouse models of AD. Dynamic PET scans were performed for
60 min after [18F]flutemetamol injection, and presented time-radioactivity
curves represent 18F-radioactivity uptake and washout in the frontal
cortex (FC) and cerebellum (CB), expressed as percent of the injected
dose (ID) per gram of brain tissue (%ID/g). Data are representative of
(a) APP23 (21 months), (b) Tg2576 (22 months) and (c) APPswe-PS1dE9
(19 months) transgenic mice. (Insets) FC/CB ratios were calculated for
60 min dynamic scans. Only APP23 mice showed higher 18F-radioactivity
in FC than in CB in the later time frames; thus, they had increasing
FC-to-CB ratios.
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N = 1) in younger TG mice, increasing to 1.15 (15 months,
N = 1), 1.16 and 1.35 (18 months, N = 2) and 1.31
(21 months, N = 1) in older TG mice. In strain-matched
WT mice, FC/CB50-60 values were 0.86 (21 months, N = 1)
and 0.99 (27 months, N = 1). In Tg2576 mice, FC/CB50-60values were 0.80 ± 0.07 (N = 4) at 12 months (WT 0.81
and 0.79, N = 2) and 0.89 and 0.99 (N = 2) at 22 months
(WT 0.88, N = 1). In APPswe-PS1dE9 mice, FC/CB50-60
remained almost stable from 0.87 ± 0.08 (N = 3) at
12 months (WT 0.85 and 0.90, N = 2) to 0.95 and 0.90
(N = 2) at 19 months (WT 0.80 ± 0.06, N = 3). The FC/
CB50-60 ratios agreed well with the Logan DVR values in
APP23 mice (r2 = 0.76, p = 0.0049; N = 9), but similar
agreement was not seen in Tg2576 (r2 = 0.13, p = 0.1046;
N = 22) or APPswe-PS1dE9 mice (r2 = 0.03, p = 0.5256;
N = 17) (Figure 3c).
Some transgenic mice were imaged repeatedly at sev-
eral time points; this is indicated by the different sym-
bols of individual animals in Figure 3a,b. In APP23 mice,
FC/CB50-60 clearly increased from 9 to 15 months and
from 18 to 21 months. Also, DVR values showed clear
increase from 9 to 18 months. However, one TG mouse
showed lower DVR value at 21 months compared to
18 months. Some Tg2576 mice showed modest increases
in FC/CB50-60. Among APPswe-PS1dE9 mice, no in-
creases were observed in individual mice subjected to re-
peated PET scans.
In vitro binding experiment
In all brain sections from transgenic APP23, Tg2576 and
APPswe-PS1dE9 mice incubated with [18F]flutemetamol
in vitro, the bound radioactivity co-localized well with fi-
brillar Aβ plaques stained with ThS and anti-Aβ1-40 anti-
body (Figure 4). The punctate [18F]flutemetamol binding
was totally blocked in Tg2576 and APPswe-PS1dE9 sec-
tions co-incubated with 10 μM cold PIB, but only par-
tially blocked in APP23 sections, likely because of their
very high plaque load (Figure 4).
Ex vivo autoradiography
Digital autoradiograms of the FC and CB were acquired
from the brain sections of the three evaluated mouse
models and wild-type control mice (Figure 5a). Intensity
profiles (derived from the boxed regions in the FC images
of Figure 5a) showed that Aβ plaques emitted higher sig-
nals than the surrounding cortex; the maximum Aβ
plaque-to-background ratios were 3.2 and 2.6 for two
APP23 mice, and 4.8 for a Tg2576 mouse. In four APPswe-
PS1dE9 mice, [18F]flutemetamol binding to Aβ deposits in
the FC was not visually equally obvious as in the APP23
and Tg2576 TG mice. The FC intensity profiles resembled
those of WT control mice, and plaque-to-background ra-
tios did not allow sharp plaque identification and were
close to unity. The FC/CB ratios were clearly elevated for
APP23 mice compared to WT mice (Figure 5b). The single
investigated Tg2576 mouse also showed a higher FC/CB
ratio than its WT control, but all APPswe-PS1dE9 TG
mice showed lower FC/CB ratios than their WT control.
High non-specific [18F]flutemetamol binding was observed
Figure 3 Quantitation of [18F]flutemetamol binding in the brain of mouse models of AD. (a) Logan distribution volume ratios (DVR) and
(b) frontal cortex-to-cerebellum ratios from 18F-radioactivity data measured over 50 to 60 min (FC/CB50-60) were calculated for APP23, Tg2576 and
APPswe-PS1dE9 transgenic mice, at different ages. For wild-type (WT) control mice, only imaging data from the last PET evaluation are shown for
clarity. Different symbols indicate different individual mice. (c) DVRs and FC/CB50-60. Ratios correlated in APP23 mice but not in Tg2576 and
APPswe-PS1dE9 mice (linear regression, r2 = 0.76, p = 0.0049, N = 9 (APP23); r2 = 0.13, p = 0.1046, N = 22 (Tg2576); r2 = 0.03, p = 0.5256,
N = 17 (APPswe-PS1dE9)).
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TG and WT mice (Figure 5a).Ex vivo biodistribution
18F-radioactivity uptake in the brain and intracranial
structures of WT C57Bl/6N animals are shown in
Table 3. The highest 18F-radioactivity in the brain was
measured in the medulla and hindbrain. 18F-radioactivity
in the CB was higher than that in the FC. The highest18F-radioactivity was measured from the structures in-
side the nasal cavity.
Aβ deposition in the brain
The same brain sections investigated with ex vivo and
in vitro autoradiography were stained with ThS and adja-
cent sections with an anti-Aβ1-40 antibody (Figures 4
and 6) to determine the presence and localization of
Aβ deposits in the brain and their co-localization with
[18F]flutemetamol binding. In APP23 brains at 21 and
Figure 4 In vitro binding of [18F]flutemetamol to Aβ deposits in
the brain of mouse models of AD. Autoradiographs of brain
sections from transgenic (TG) APP23 (21 months), Tg2576
(22 months) and APPswe-PS1dE9 (19 months) transgenic mice show
[18F]flutemetamol binding to whole sections (left panels) and
adjacent sections treated with 10 μM cold PIB (+10 μM PIB) (right
panels). High magnifications of areas enclosed in boxes show Aβ
deposits detected with [18F]flutemetamol autoradiography (ARG,
left column), compared to the same section stained with Thioflavin
S (ThS, middle column), and an adjacent section stained with an
anti-Aβ antibody (Aβ1-40, right column). Scale bar = 200 μm. mo, age
of animal in months.
Figure 5 Ex vivo binding of [18F]flutemetamol to Aβ deposits in
the brain of mouse models of AD. (a) Representative brain
sections are shown for transgenic (TG) APP23 (27 months), Tg2576
(22 months) and APPswe-PS1dE9 (19 months) mice and wild-type
(WT) control mice. Plaque-to-background ratios were calculated from
the intensity profiles derived from the areas enclosed in black boxes
(FC column). (b) Frontal cortex (FC) to cerebellum (CB) ratios were
calculated for TG (filled symbols) and WT (open symbols) animals
at different ages. The red symbols represent the ratios from the
individual TG animals presented in (a). mo, age of animal in months.
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core were seen in the FC and in other forebrain regions,
but not in the CB. Deposits were prominently stained
with ThS and anti-Aβ1-40. The plaque load was modest
in Tg2576 brain at 22 months, but the deposits were
stained with ThS and anti-Aβ1-40 antibody and the stain-
ing co-localized with [18F]flutemetamol binding in the
FC. In APPswe-PS1dE9 mice, Aβ deposits were small,
spherical and showed low intensity staining with ThS at
19 months. However, deposition was abundant through-
out the brain, including the CB, at 19 months. WT mice
did not have detectable Aβ deposits (Figure 6).
Discussion
In the present study, we evaluated the applicability of
[18F]flutemetamol to assess brain Aβ deposition in small
animal in vivo PET imaging. [18F]Flutemetamol has
already been extensively investigated in humans and has
received marketing approval as a radiopharmaceutical
for the detection of Aβ deposition in subjects with pos-
sible AD [12,23-25]. In our previous animal study, we
found that the pharmacokinetic properties of [18F]flute-
metamol in WT rats and mice were suitable for preclin-
ical imaging, and [18F]flutemetamol was found to bind
to Aβ deposits in the Tg2576 mouse brain, both in vitro
and ex vivo [9]. To our knowledge, the present demon-
stration of principle study is the first to show that it is
possible to detect increase in [18F]flutemetamol reten-
tion in vivo in the mouse brain parallel with increasing
age. However, in the present study, increased [18F]flutemetamol retention was evident only in the trans-
genic APP23 mice and not in Tg2576 or APPswe-
PS1dE9 mice. APP23 mouse model is known to have
relatively slow plaque deposition and large Aβ deposits
with dense amyloid cores [4,18]. Tg2576 mice have late
onset and even slower rate of Aβ deposition than APP23
mice [4]. In APPswe-PS1dE9 mice, small Aβ deposits are
present already at earlier age, and deposition is abundant
throughout the brain in older animals [4].
Varying results have been found in several small ani-
mal imaging studies with [11C]PIB, a structural analogue
of [18F]flutemetamol which is still considered the golden
standard of brain amyloid imaging. A possible explan-
ation for the variation is that different TG mice are likely
to express different Aβ isoforms with different amounts
of high-affinity binding sites for amyloid tracers [26].
We hypothesized that very high specific activity and
lower injected mass of [18F]flutemetamol might provide
an advantage in some animal models that did not show
increased specific binding with [11C]PIB in our previous
study, perhaps because of low levels of high-affinity
binding sites [4]. In this study, the injected mass of [18F]
















Cranial bone 0.83 0.13
Submandibular salivary gland 0.16 0.02
Sublingual gland 0.28 0.03
Harderian gland 0.36 0.05
Eyes 0.93 0.11
Nasal cavity 1.89 0.47
Uptake of [18F]flutemetamol in the brain and adjacent tissues of C57Bl/6 N
mice at 60 min post-injection of the tracer (N = 4). Values are presented as
percentage of injected dose per gram of tissue (% ID/g).
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(N = 48). This is even at its worst ten times less than
previously reported with [11C]PIB (68 ± 23 ng; N = 50
[4]). However, the results revealed that the use of a
tracer with high specific radioactivity did not as such
provide any advantage in PET imaging of APPswe-
PS1dE9 mice in vivo. In APPswe-PS1dE9 mice, plaque
deposition was abundant throughout the brain (includ-
ing the CB) at 19 months, but plaque composition ap-
peared to be different from the other TG models, with
only small fibrillar deposits that could bind ThS and re-
lated Aβ imaging agents. In Tg2576 mice, modest in-
creases in DVR and FC/CB50-60 ratio were seen as the
individual transgenic mice aged. In a previous study with
[11C]PIB and Tg2576 mice, no such trend was seen [4].
In addition, [18F]flutemetamol did bind to Aβ in the cor-
tical sections from Tg2576 animals, both ex vivo and
in vitro, consistent with previous ex vivo results [9].
However, the amount of plaques was modest even at
22-month-old animals, explaining the modest increases
in in vivo binding ratios. We concluded that Tg2576 and
APPswe-PS1dE9 mouse models are not suited to small
animal imaging studies with tracers that shared binding
sites with [11C]PIB and [18F]flutemetamol, due to their
plaque structure or low plaque load.Our study is difficult to compare with previous small
animal amyloid imaging PET studies that used other 18F-
labelled tracers, due to the differences in tracers, quantita-
tion methods and animal models used. One previous
study did not observe increased cortical tracer retention
with [18F]FDDNP in 13 to 15-month-old Tg2576 mice
[27]. The authors concluded that specific [18F]FDDNP
binding was insufficient and that insufficient spatial reso-
lution and partial volume effects (PVE) limited the preci-
sion of measurements in small VOIs [27]. However, in a
more recent study with [18F]florbetaben, Aβ deposition
was longitudinally followed in the APPswe mouse model
from age 13 to 20 months, and the results were consistent
with our results with [18F]flutemetamol in APP23 mice. In
that study, the PET results agreed well with histopatho-
logical brain Aβ, and differentiation was further improved
when a PVE correction was applied [10,28]. Using the
APP-PS1-21 mouse model, also specific binding of [18F]
florbetapir was shown to increase from age 3 to 8 months;
however, no further increase was detected at 12 months
compared to the baseline scan at 3 months [11]. At the
end of synthesis, the specific activities of [18F]florbetaben
(80 GBq/μmol, [10]) and [18F]florbetapir (150 to
220 GBq/μmol, [11]) were much lower than the specific
activity of [18F]flutemetamol in this study (>1 TBq/μmol).
This difference further supports the higher importance of
the chosen mouse model over high specific activity of the
tracer for successful imaging results.
Similarly to human studies, the CB has usually been
used as a reference region in small animal amyloid im-
aging studies. However, several limitations should be
considered when applying this approach. In the mouse
brain, the white and grey matter cannot be distinguished
when the reference region VOIs are drawn over the CB,
due to its small size. As a result, because all 18F-labelled
β-amyloid imaging tracers typically exhibit prominent
white matter binding, the concentration of radioactivity
in the CB can be higher than that in the cortical grey
matter ROIs. In our study, DVRs were less than unity in
WT animals and in young TG animals, which presum-
ably had only modest plaque loads. Negative BPND
values for WT and young TG mice were also previously
reported for [18F]florbetaben. Only TG mice that were
16 and 20 months old showed positive BPNDs (0.04 ±
0.07 and 0.10 ± 0.11, respectively) [10]. For small animal
imaging, tracers with low non-specific binding to white
matter would be beneficial, such as the novel 18F-
labelled fluoropyridyl derivative, BAY 1008472, or the
benzofuran ligand [18F]AZD4694 [29,30]. Moreover, for
APPswe-PS1dE9 mice, the CB is not a suitable reference
region because Aβ deposits are present at 19 months
of age.
Imaging of small structures in the mouse brain, of a
size close to the spatial resolution of the PET scanner,
Figure 6 Aβ deposition in the brain of mouse models of AD. (a) Representative images show Thioflavin S staining for transgenic (TG) APP23
(27 months), Tg2576 (22 months) and APPswe-PS1dE9 (19 months) mice and wild-type (WT) control mice in the same sections used for ex vivo
evaluation of [18F]flutemetamol binding in Figure 5. (b) Adjacent sections from TG APP23 (27 months), Tg2576 (22 months) and APPswe-PS1dE9
(19 months) mice and WT control mice were stained with specific anti-Aβ1-40 antibody mo, age of animal in months.
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nals will be less precise than those achievable with
digital autoradiography. Consistent with previous [18F]
florbetaben and [18F]florbetapir studies, the FC/CB ra-
tios observed in our study with [18F]flutemetamol with
ex vivo autoradiography (1.8 and 1.9, respectively, at
30 min p.i.) were higher than that observed with in vivo
PET (1.3 at 30 to 35 min p.i.) for old APP23 mice. Add-
ing PVE correction could further improve quantitation
of [18F]flutemetamol PET data, especially in animals
with still only modest plaque load. Also, spillover from
tissues close to the brain could introduce errors to
the VOI-based analysis method in mice. We observed
high radioactivity in close proximity to the brain in vivo,
and subsequent ex vivo tissue counting experiments
confirmed that significant radioactivity was located
outside of the brain, inside the nasal cavity. In addition,
18F-radioactivity concentrations detected in the mouse
cranial bone (0.83 ± 0.13% ID/g at 30 min) were higherthan those previously reported in rats (0.04 ± 0.01% ID/g
at 30 min [9]); this suggests that more [18F]flutemetamol
defluorination could be taking place in mice than in
rats, reflecting more active metabolism. However, spill-
over from these structures would presumably lead to
similar overestimation in the brains of all three TG
mouse models.
One limitation of the present study was the small
number of transgenic animals, especially the ones that
could be imaged repeatedly over multiple time points.
However, we wanted to evaluate the applicability of [18F]
flutemetamol PET to small animal imaging in three dif-
ferent transgenic models even with limited statistical
power, rather than in only one transgenic model with
higher sample size and better statistical power. This
demonstration of principle type of study was still able to
show clear increasing trend in [18F]flutemetamol binding
in aging APP23 mice and the lack of binding in Tg2576
and APPswe-PS1dE9 mice. Another limitation was that
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male mice imaged in vivo; however, the brain sections
from these mice were used for in vitro binding experi-
ments, and additional ex vivo studies were performed
later, with aged males. Male APP23 mice were reported
to show slightly slower deposition of Aβ plaques com-
pared to females [17], but these mice were 27 months
old; thus, Aβ deposition was abundant. In addition, a hy-
brid PET/MRI scanner with better spatial resolution and
MR details of the brain would better serve the purposes
of similar experiments.
Conclusions
In vivo small animal imaging of brain Aβ with [18F]flute-
metamol, similarly to its structural analogue [11C]PIB, is
more dependent on which AD mouse model is used
than its high specific activity. In this study, Aβ depos-
ition in the brain could only be followed in vivo in
APP23 mice. However, for its practical benefits, such as
more efficient use of the produced tracer batches, [18F]
flutemetamol imaging with a suitable mouse model like
APP23 is an attractive alternative.
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